Eli Lilly puts $1.3B in biobucks on the line for Foghorn’s oncology programs
Eli Lilly is throwing more cash at its $8 billion bet on Loxo Oncology, this time via a $380 million confidence boost in Foghorn Therapeutics to go after multiple cancers.
Eli Lilly is throwing more cash at its $8 billion bet on Loxo Oncology, this time via a $380 million confidence boost in Foghorn Therapeutics to go after multiple cancers.
Five years into its lofty goal of funding projects to “cure, prevent or manage all disease within our children’s lifetime,” the Chan Zuckerberg Initiative’s Biohub is getting a major boost.
After three months of testimony from an array of former Theranos employees, investors and clients, culminating in a seven-day stint on the stand for Elizabeth Holmes—the defunct blood-testing company’s founder and former CEO, who’s currently on trial for 11 counts of fraud—Holmes’ defense has rested its case.
Eli Lilly is making a $1.5 billion biobucks bet on Chinese biotech Regor Therapeutics to seek out, develop and hopefully sell new therapies for metabolic disorders.
The difficult-to-enter landscape of amyotrophic lateral sclerosis (ALS) R&D received a major boost Wednesday night from the U.S. House of Representatives as 423 of 433 legislators passed a bill that would funnel $500 million into treatments for the muscle-wasting disease.
The Nordic life sciences scene is getting an injection of cash. Led by centers such as the Karolinska Institute and Copenhagen University, the region leads the way in research in the EU by many metrics but has traditionally lacked the vibrant VC scene needed to build large numbers of biotechs. Eir Ventures wants to help change that.
Several months after the U.S. Department of Justice (DOJ) signed off on Microsoft’s plan to acquire the artificial intelligence software developer Nuance Communications, its watchdog counterpart across the pond is taking a closer look at the proposed buyout.
A Canadian startup aims to give the decades-old, hand-performed ELISA test a 21st century upgrade by transforming the humble immunoassay into a high-throughput protein profiling platform.
Totus Medicines is making a play for the PI3Kα inhibitor market. Exiting stealth with a $40 million series A round, the Massachusetts-based biotech plans to advance a molecule designed to improve on existing PI3Kα inhibitors such as Novartis’ Piqray.
Merck KGaA is upping its commitment to corporate venture capital with a 600 million euro ($677 million) investment, positioning its VC arm M Ventures to up the number and size of its bets over the next five years.